COMPANY INFO
Pendulum, founded in 2012 and headquartered in San Francisco, is a biotechnology company specializing in microbiome interventions and drugs designed to improve healthcare by managing chronic illnesses and type 2 diabetes. The company was co-founded by Colleen Cutcliffe (CEO), John Eid (CSO), and Jim Bullard, all scientists with extensive backgrounds in microbiology and biochemistry. Pendulum has approximately 143 employees as of 2025 and operates primarily in the Other Consumer Non-Durables industry. Their mission is to create microbiome products that combine the power and efficacy of pharmaceuticals with the safety and accessibility of probiotics. The official website is https://pendulumlife.com.
Pendulum Therapeutics, Inc., founded in 2012 and headquartered in San Francisco, operates within the biotechnology sector, focusing on microbiome interventions and drug development to address chronic illnesses, particularly type 2 diabetes. Co-founded by Colleen Cutcliffe (CEO), John Eid (CSO), and Jim Bullard, Pendulum leverages scientific advancements in microbiology and biochemistry to develop innovative therapeutics that blend pharmaceutical rigor with the accessibility of probiotics.
Pendulum Therapeutics, Inc. funding history showcases a robust approach to venture capital, having secured approximately $149 million across multiple funding rounds. The company’s funding strategy has attracted support from prominent investors such as Fonterra, Meritech, Sequoia Capital, and True Ventures. Spanning at least four major funding rounds—including seed, Series B, and multiple Series C investments—Pendulum’s funding journey has supported critical milestones in research, development, and market expansion. The proceeds from these rounds have fueled product development, clinical trials, and commercial scaling of its microbiome-based therapeutics, positioning Pendulum as a leader in evidence-based gut health solutions.
This latest Series C round led by Fonterra was aimed at supporting continued product development, market expansion, and scaling of Pendulum’s commercial efforts.
The $54 million raised in this Series C round, led by Meritech, was designated for accelerating growth and expanding Pendulum's product pipeline, strengthening their market presence in microbiome therapeutics.
The Series B funding round, led by Sequoia Capital and True Ventures, focused on market expansion and scaling the company’s operations to enhance reach and distribution of their products.
Pendulum’s $4 million seed round, with Sequoia Capital and True Ventures as leading investors, provided the initial capital for early product development and company launch.
Fonterra led Pendulum’s most recent Series C round. Fonterra is a multinational dairy cooperative based in New Zealand known for investing in innovations in health and nutrition. Their support underscores confidence in Pendulum’s microbiome science and commercial vision.
Meritech, a prominent venture capital firm specializing in late-stage investments, played a pivotal role in Pendulum’s $54 million Series C round. Their backing has enabled Pendulum to accelerate its growth trajectory and product expansion strategy.
Sequoia Capital is a globally recognized venture capital firm that invested in both the seed and Series B rounds. Their early and continued investment has provided strategic guidance and credibility, enabling Pendulum to scale from scientific research into commercial reality.
True Ventures is an early-stage venture capital firm that co-led Pendulum’s seed and Series B rounds. Their support was instrumental in turning Pendulum’s scientific innovation into market-ready solutions.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Pendulum Therapeutics, Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.